Aptose Reports Results for the First Quarter 2023

08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for ...

Related Keywords

Canada ,Toronto ,Ontario ,United States ,American ,Canadian ,Tuspetinib Monotherapy ,Aptose Biosciences ,Susan Pietropaolo ,American Society Of Hematology ,European School Of Haematology ,Exchange Commission ,Drug Administration ,Aptose Biosciences Inc ,Corporate Communications Investor Relations ,European Hematology Association ,Brisk Enrollment ,Doublet Arms ,Clinical Activity Already Noted ,Tuspetinib Superior Safety Profile Continues ,Chief Executive ,Safety Review ,Dose Escalation ,Exploration Arms ,Hematology Association ,American Society ,Annual Meeting ,Operations Data ,Call Webcast ,Webcast Only ,Participant Registration ,Investor Relations ,United States Securities ,Managing Director ,